ATE492277T1 - Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-( -(pyridin-3-yl)pyrimidin-2- ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms - Google Patents
Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-( -(pyridin-3-yl)pyrimidin-2- ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fmsInfo
- Publication number
- ATE492277T1 ATE492277T1 AT05793868T AT05793868T ATE492277T1 AT E492277 T1 ATE492277 T1 AT E492277T1 AT 05793868 T AT05793868 T AT 05793868T AT 05793868 T AT05793868 T AT 05793868T AT E492277 T1 ATE492277 T1 AT E492277T1
- Authority
- AT
- Austria
- Prior art keywords
- fms
- ylamino
- benzamide
- ylmethyl
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61974404P | 2004-10-18 | 2004-10-18 | |
PCT/AU2005/001602 WO2006042362A1 (en) | 2004-10-18 | 2005-10-17 | Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE492277T1 true ATE492277T1 (de) | 2011-01-15 |
Family
ID=36202610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05793868T ATE492277T1 (de) | 2004-10-18 | 2005-10-17 | Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-( -(pyridin-3-yl)pyrimidin-2- ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms |
Country Status (19)
Country | Link |
---|---|
US (1) | US20080255139A1 (de) |
EP (1) | EP1804800B1 (de) |
JP (1) | JP2008516898A (de) |
KR (1) | KR20070083705A (de) |
CN (1) | CN101035535A (de) |
AT (1) | ATE492277T1 (de) |
AU (1) | AU2005297321A1 (de) |
BR (1) | BRPI0517083A (de) |
CA (1) | CA2580976A1 (de) |
DE (1) | DE602005025514D1 (de) |
IL (1) | IL182419A0 (de) |
MA (1) | MA28946B1 (de) |
MX (1) | MX2007004660A (de) |
NO (1) | NO20072501L (de) |
NZ (1) | NZ554009A (de) |
RU (1) | RU2007118420A (de) |
TN (1) | TNSN07141A1 (de) |
WO (1) | WO2006042362A1 (de) |
ZA (1) | ZA200702316B (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009058968A2 (en) * | 2007-10-31 | 2009-05-07 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to fms treatment |
JP6852848B2 (ja) * | 2015-01-13 | 2021-03-31 | 国立大学法人京都大学 | 筋萎縮性側索硬化症の予防及び/又は治療剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837237A (en) * | 1985-07-09 | 1989-06-06 | Fred Hutchinson Cancer Research Center | Therapy using glucosidase processing inhibitors |
ATE331519T1 (de) * | 2001-05-16 | 2006-07-15 | Gpc Biotech Ag | Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten |
US20060052387A1 (en) * | 2002-06-26 | 2006-03-09 | Marsh Clay B | Organic compounds |
-
2005
- 2005-10-17 CA CA002580976A patent/CA2580976A1/en not_active Abandoned
- 2005-10-17 WO PCT/AU2005/001602 patent/WO2006042362A1/en active Application Filing
- 2005-10-17 JP JP2007535954A patent/JP2008516898A/ja active Pending
- 2005-10-17 EP EP05793868A patent/EP1804800B1/de active Active
- 2005-10-17 CN CNA2005800338341A patent/CN101035535A/zh active Pending
- 2005-10-17 US US11/576,967 patent/US20080255139A1/en not_active Abandoned
- 2005-10-17 MX MX2007004660A patent/MX2007004660A/es unknown
- 2005-10-17 RU RU2007118420/15A patent/RU2007118420A/ru unknown
- 2005-10-17 AT AT05793868T patent/ATE492277T1/de not_active IP Right Cessation
- 2005-10-17 KR KR1020077008716A patent/KR20070083705A/ko not_active Application Discontinuation
- 2005-10-17 BR BRPI0517083-4A patent/BRPI0517083A/pt not_active IP Right Cessation
- 2005-10-17 DE DE602005025514T patent/DE602005025514D1/de active Active
- 2005-10-17 AU AU2005297321A patent/AU2005297321A1/en not_active Abandoned
- 2005-10-17 NZ NZ554009A patent/NZ554009A/en not_active IP Right Cessation
-
2007
- 2007-03-20 ZA ZA200702316A patent/ZA200702316B/xx unknown
- 2007-04-10 IL IL182419A patent/IL182419A0/en unknown
- 2007-04-17 TN TNP2007000141A patent/TNSN07141A1/fr unknown
- 2007-04-25 MA MA29848A patent/MA28946B1/fr unknown
- 2007-05-15 NO NO20072501A patent/NO20072501L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA200702316B (en) | 2008-09-25 |
DE602005025514D1 (de) | 2011-02-03 |
CN101035535A (zh) | 2007-09-12 |
NZ554009A (en) | 2010-09-30 |
KR20070083705A (ko) | 2007-08-24 |
MA28946B1 (fr) | 2007-10-01 |
EP1804800A1 (de) | 2007-07-11 |
RU2007118420A (ru) | 2008-11-27 |
AU2005297321A1 (en) | 2006-04-27 |
MX2007004660A (es) | 2007-10-17 |
CA2580976A1 (en) | 2006-04-27 |
TNSN07141A1 (en) | 2008-11-21 |
IL182419A0 (en) | 2007-09-20 |
JP2008516898A (ja) | 2008-05-22 |
WO2006042362A1 (en) | 2006-04-27 |
US20080255139A1 (en) | 2008-10-16 |
EP1804800A4 (de) | 2008-03-19 |
BRPI0517083A (pt) | 2008-09-30 |
EP1804800B1 (de) | 2010-12-22 |
NO20072501L (no) | 2007-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY148375A (en) | Delta and epsilon crystal forms of imatinib mesylate | |
PT1332137E (pt) | Tratamento de tumores estromais gastrintestinais | |
IL177005A0 (en) | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
NZ598924A (en) | Compounds comprising pyrimidyl and pyrazolyl moieties and compositions as protein kinase inhibitors | |
PE20121476A1 (es) | Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r | |
PE20120626A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
NO20075624L (no) | Nye histamin H3-reseptorligander og deres terapeutiske anvendelser | |
MY146403A (en) | F, g, h, i and k crystal forms of imatinib mesylate | |
ATE474835T1 (de) | Als inhibitoren von proteinkinasen geeignete aminopyrimidine | |
ATE457311T1 (de) | Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine | |
ATE542814T1 (de) | Pyrazinkinaseinhibitoren | |
HUE034712T2 (hu) | Amidszármazék és gyógyszer | |
NO20075022L (no) | (7-(2-(4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyrid-1-yl)etyl) isokinolinbesylatsalt, fremstilling og terapeutiske anvendelser derav | |
EA201070366A1 (ru) | 3-метил-2-((2s)-2-(4-(3-метил-1,2,4-оксадиазол-5-ил)фенил)морфолино)-6-(пиримидин-4-ил)пиримидин-4(3н)-он в качестве ингибитора тау-протеинкиназы | |
WO2008059551A3 (en) | Process for the preparation of imatinib and intermediates thereof | |
BR0312873A (pt) | 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante | |
NZ590177A (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis | |
ES2421587T3 (es) | Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica | |
HRP20100265T1 (hr) | Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti | |
JP2008542390A5 (de) | ||
EA200702027A1 (ru) | Дерматологические композиции и соли для лечения дерматологических заболеваний | |
ATE492277T1 (de) | Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-( -(pyridin-3-yl)pyrimidin-2- ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms | |
NO20056188L (no) | Anvendelse av en c-Abl-, PDGF-R- eller c-kit-tyrosinkinaseinhibitor for behandling av diabetes | |
BR0307286A (pt) | Tratamento de artrite reumatóide usando imatinib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |